Sellas Life Sciences Group Inc (NASDAQ:SLS)
| 1.34 Delayed Data As of Mar 17 |  -0.03 / -2.17%Today’s Change | 1.27 Today|||52-Week Range 7.40 | -43.22% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $38.2M |
Company Description
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Contact Information
SELLAS Life Sciences Group, Inc. 7 Times Square New York New York 10036 |
Employees
Shareholders
| Mutual fund holders | 5.59% |
| Other institutional | 5.17% |
| Individual stakeholders | 1.83% |
Top Executives
| Angelos M. Stergiou | President, Chief Executive Officer & Director |
| John T. Burns | SVP, Chief Financial Officer & Accounting Officer |
| Dragan Cicic | Senior Vice President-Clinical Development |
| Barbara A. Wood | Secretary, Executive VP & General Counsel |
| Andrew Elnatan | VP, Head-Regulatory Affairs & Chemistry |
